Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Hepatitis C; Chronic Clinical Trials

A listing of Hepatitis C; Chronic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (67) clinical trials

Re-treatment of HCV Following DAA Failure

-Introduction Oral drugs, termed collectively as 'Direct-acting anti-viral agents' (DAAs), are the standard-of-care for HCV treatment. In India, four DAAs, namely sofosbuvir (SOF), daclatasvir (DCV), ledipasvir (LDV) and velpatasvir (VEL), are marketed. Initially, people were treated using SOF in combination with ribavirin with or without pegylated-interferon (Peg-IFN). Thereafter, HCV treatment ...

Phase N/A

Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model

An algorithm was developed using SOF-based regimens to treat all patients (RKD). Genotyping is not recommended for patients without cirrhosis of liver and they are being treated with SOF+DCV for 12-weeks, while genotyping is recommended for patients with cirrhosis of liver (Figure 1). Patients with liver cirrhosis and genotype 3 ...

Phase N/A

DAA Therapy in Pediatric Patients With Chronic Hepatitis C

Consecutive chronic hepatitis C (HCV) infected children [age: 12 to <18 years; both treatment-nave (TN) and treatment-experienced, (TE)] are being enrolled. Genotyping is not recommended for non-cirrhotic or TN patients and were treated with SOF+DCV for 12-weeks, while genotyping is recommended for patients with cirrhosis and TE patients. Patients with ...

Phase N/A

Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]

This will be a non-blinded randomized clinical trial with 150 participants randomized at a 1:1:1 allocation ratio to one of three treatment arms. Arm 1: Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180g/weekly) for 4 weeks with a field-based DOT approach Arm 2: Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) ...

Phase

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)

Patients who receive direct-acting anti-HCV treatment will be prospectively studied during 2-year period. All patients have HCV/HBV co-infection. The inclusion/exclusion criteria and the follow up plan will be listed in following part.

Phase

Switching Regimen in Treating Cirrhotic HCV GT1b Subjects

This is a prospective, randomized study to evaluate the efficacy and safety of switching treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with CHC genotype 1b infection, who are interferon/ribavirin-intolerant.

Phase

Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection

Incorporating HCV treatment into opioid maintenance treatment program clinical protocols is an innovative health care delivery model that has been associated with improved HCV treatment uptake in non-pregnant, drug-using populations. This "medical home" approach would combine HCV and opioid maintenance treatment into one treatment regimen and incorporate the expertise of ...

Phase

Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics

determine the cure rate of Harvoni in treatment nave alcoholic subjects with Genotype 1 HCV infection

Phase

Liver Trial on Oral Tocotrienol

As a safe and natural vitamin, tocotrienol (TCT) stands uniquely poised to treat ~500 million worldwide who suffer from viral hepatitis. Furthermore, for those awaiting liver transplantation, TCT may buy more time until a liver becomes available. The primary purpose of this Phase IIA trial is to validate the outcome ...

Phase

Live Kidney Donors With Positive Anti-HCV Antibody But Negative HCV PCR

Individuals who test positive for anti-HCV IgG antibody, but who have negative blood HCV RNA PCR are generally considered to have been infected with HCV but to have cleared the the virus spontaneously. However, due to the general conservative approach of living donor kidney transplant programs, these individuals are not ...

Phase N/A